Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)

Date

09 Oct 2016

Session

Poster display

Presenters

Viktor Grünwald

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

V. Grünwald1, M. Dietrich2, G.R. Pond3

Author affiliations

  • 1 Clinic For Hematology, Hemostasis, Oncology And Stemcelltransplantation, Hannover Medical School, 30625 - Hannover/DE
  • 2 Natural Sciences, Leibniz University Hannover, Hannover/DE
  • 3 Oncology, Escarpment Cancer Research Institute, McMaster Medical Centre, Hamilton/CA
More

Resources

Background

MSKCC and IMDC risk classification scores consist of clinical and laboratory parameters, which are able to classify patients prognosis. Baseline health related quality of life (HR-QoL) has been previously shown to have prognostic relevance in cancers. We therefore tested whether the addition of HR-QoL parameters to these tools can improve prognostic accuracy.

Methods

1100 1st line patients treated with sunitinib or pazopanib within the COMPARZ study (NCT00720941) were analyzed retrospectively. Baseline FACIT-Fatigue (F), FKSI-19 and the DRS-P subscale were used as continuous variable in prognostic factor analysis. Cox proportional hazards regression was performed to evaluate the potential prognostic ability of HR-QoL parameters on OS. Scores were adjusted for MSKCC and IMDC risk group scores separately.

Results

Univariable analysis on prognosis, adjusted for risk groups.

HR (CI95%) P
IMDC risk FACIT-F Favorable Intermediate Unfavorable Unknown Continuous 0.77 (0.37, 1.60) 1.42 (0.70, 2.87) 3.10 (1.50, 6.38) REFERENCE 0.97 (0.97, 0.98)

Conclusions

Our analyses indicate that baseline HR-QoL scores add to established risk prognosticators. However, only a single HR-QoL score should be used for further validation. Further study of discrimination ability is ongoing.

Clinical trial identification

NCT00720941

Legal entity responsible for the study

GSK sponsored clinical study, which is the data set for the current retrospective analysis

Funding

Medical School Hannover, Leibniz University, McMaster University

Disclosure

V. Grünwald: Honoraria: BMS, Novartis, Pfizer. Consultation: BMS, Novartis, Pfizer. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.